摘要
目的观察替米沙坦联合芪参益气滴丸对糖尿病早期肾病患者血清淀粉样蛋白A(SAA)、白细胞介素-6(IL-6)及肿瘤坏死因子-α(TNF-α)的影响。方法入选我院收治90例糖尿病早期肾病患者,随机分为试验组和对照组,各45例。对照组给予替米沙坦,每次40 mg,每天1次。试验组在对照组的基础上给予芪参益气滴丸,每次0. 5 g,每天3次。2组均治疗6个月。观察治疗前后2组患者的空腹血糖(FBG)、糖化血红蛋白(Hb A1c)、血清肌酸酐(SCr)、尿蛋白排泄率(UAER)、尿β2微球蛋白(β2-MG)、血清SSA、IL-6、TNF-α等变化情况。结果治疗后,试验组和对照组的总有效率分别为82. 22%(37例/45例),57. 78%(26例/45例),差异有统计学意义(P <0. 05)。治疗后6个月,试验组血清SSA,IL-6,TNF-α水平分别为(8. 85±1. 25)μg·L^(-1),(201. 52±11. 05) pg·m L^(-1),(2. 85±0. 21) ng·m L^(-1),对照组分别为(11. 25±1. 26)μg·L^(-1),(236. 58±6. 12) pg·m L^(-1),(3. 25±0. 37) ng·m L^(-1),差异均有统计学意义(均P <0. 05)。治疗后6个月,试验组的FBG、Hb A1c、SCr、UAER和β2-MG分别为(7. 2±0. 5) mmol·L^(-1),(7. 0±0. 1)%,(58. 6±0. 6)μmol·L^(-1),(67. 2±2. 2)μg·min^(-1),(198. 5±10. 5)μg·L^(-1);对照组分别为(7. 8±0. 8) mmol·L^(-1),(7. 6±0. 2)%,(67. 2±0. 9)μmol·L^(-1),(88. 9±1. 9)μg·min^(-1),(270. 5±13. 5)μg·L^(-1),差异均有统计学意义(均P <0. 05)。2组治疗过程中均未见明显的药物不良反应发生。结论芪参益气滴丸治疗糖尿病早期肾病患者有助于降低尿白蛋白排出,抑制炎症损伤,保护肾功能。
Objective To observe the effects of telmisartan combined with Qishen Yiqi drops on serum amyloid A （SAA）, interleukin -6 （IL- 6） and tumor necrosis factor-α （TNF-α） in patients with early diabetic nephropathy. Methods Ninety patients with early diabetic nephropathy treated in our hospital were randomly divided into treatment group and control group, each group 45 cases. Control group was treatec with telmisartan 40 mg, once a day. Treatment group was treated with Qishen Yiqi drops 0.5g, 3 times a day, on the basis of control group. The fasting plasma glucose （ FBG）, glycosylated hemoglobin （ HbAIc ）, serum creatinine （ SCr ） , urinary albumin excretion rates （ UAER）, β2 - microglobulin （ β2 - MG）, serum amyloid A （SAA）, interleukin -6 （ IL - 6） and tumor necrosis factor -α （ TNF -α） in two groups were compared. Results After treatment, the total efficacy in treatment group and control group were 82.22% （37 cases/45 cases） , 57.78% （26 cases/45 cases） , with significant difference （P 〈 0. 05 ）. After 6 months treatment, the SSA, IL- 6, TNF-α in treatment group were （ 8.85±1.25 ） μg· L^-1, （ 201.52±11.05 ） pg·mL^-1, （ 2.85±0. 21 ） ng·mL^-1, all had significant difference with those in control group, which were （ 11.25 ± 1.26） μg·L^-1, （ 236.58±6. 12 ） pg·mL^-1, （ 3.25 ± 0. 37 ） ng·mL^-1 （all P 〈 0.05）. After 6 months treatment, FBG, HbAle, SCr, UAER and β2 -MG in treatment group were （71 2±0. 5）mmol·L^-1, （7.0±0. 1）%, （58.6 ±0. 6） μmol·L^-1, （67.2 ± 2.2） μg·min^-1, （198.5 s 10. 5） μg·L^-1;all had significant difference with those in control group, which were （7.8 ±0.8 ）mmol·L^-1, （7.6±0. 2） %, （67.2±0.9） μmol·L^-1 , （88.9±1.9）μg·min-1, （270. 5±13.5 ）μg·min^-1 （ all P 〈0. 05 ）. There were no obvious adverse drug reactions in two groups. Conclusion Qishen Yiqi drops in the treatment of patients with early diabetic nephropathy can help reduce urinary albumin excretion, inhibit inflammatory damage and protect kidney function.
作者
王美芹
张建志
WANG Mei-qin;ZHANG Jian-zhi(Department of Traditional Chinese Medicine,Harrison International Peace Hospital,Hengshui 053000,Hebei Province,China;Department of Eliminate Pests,Hengshui Center for Disease Prevention and Control,Hengshui 053000,Hebei Province,China)
出处
《中国临床药理学杂志》
CAS
CSCD
北大核心
2018年第22期2610-2612,共3页
The Chinese Journal of Clinical Pharmacology
